

**Bilcare's Consolidated Net Sales increase to Rs. 1047.83 Cr;  
Overseas Net Profit grows by 86.51 per cent for the year ended 31<sup>st</sup> March, 2010**  
~ Board of Directors recommends Annual Dividend of 25 per cent ~

**Pune, 23 July 2010:** Bilcare Ltd. (BSE code: 526853), a leading service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31, 2010.

The consolidated net sales for the year ended March 31, 2010 stood at Rs. 1,047.83 crore showing a growth of 22.41 per cent as against Rs. 856.02 crore in the corresponding period of the previous year. The company recorded a net profit of Rs 116.95 crore showing a growth of 41.01% against Rs. 82.94 crore in the same period last fiscal. The EBIDTA stood at Rs. 206.37 crore, showing a growth of 31.97% against Rs. 156.37 crore in the corresponding period of the previous year.

The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of shareholders.

**Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited** announced: "I am delighted to announce a steady growth in our established business of pharma packaging innovation and clinical supplies. The prospects for our newly launched technology, which is now being executed for the Delhi Police Force, are equally exciting. This technology is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, it has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian country."

He added, "Bilcare is about to close a deal with a European consumer product company. On the document security front, a major trial is underway with a printer manufacturer in USA."

The Standalone Sales in India for the quarter end (Q4FY10) stood at Rs.145.71 crore as against Rs.121.86 crore in the same quarter of the previous year, showing a growth of 19.57 per cent. This resulted in the EBIDTA for India Standalone growing to Rs.47.01 crore from Rs.37.32 crore in the corresponding quarter of the previous year, showing a growth of 25.96 per cent. The India standalone sales for the year ended March 31, 2010, stood at Rs. 549.65 crore as against Rs.471.33 crore of the previous year. The net profit on a standalone basis for India stood at Rs 75.47 crore registering a growth of 24.33 per cent and EBIDTA for the year stood at Rs.165.74 crore registering a growth of 26.67 per cent.

Overseas Sales for the year ended March 31,2010, stood at Rs.498.18 crore against Rs.384.69 crore in the previous year, showing a growth of 29.50 per cent. Similarly, EBIDTA and Net Profit for the year ended stood at Rs.94.18 crore and Rs.41.48 crore respectively, showing a growth of 48.62 per cent in EBIDTA and 86.51 per cent in Net Profit.

**About Bilcare:**

Bilcare is an internationally integrated service provider to the global pharmaceutical industry offering innovative pharma packaging & research, global clinical trial supplies



services and anti-counterfeiting technologies for the pharmaceuticals; while Bilcare Technologies under its nonClonableID™ offers identification , authentication and secure track-n-trace technologies Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare provides solutions that address many of the industry's key concerns including the Five Key concerns - (5 C's) viz. counterfeit, compliance, communication, convenience and cost.

For further details contact:

Bilcare Research

Tel: +91 20 30257700

Email: [corpcomm@bilcare.com](mailto:corpcomm@bilcare.com)